Amgen’s KRAS G12C Inhibitor Product Sotorasib Has Thrilling Results

Amgen and the KRAS G12C Protein Discovery
The RAS gene family has been a subject for four decades of research. The family contains some of the most frequently mutated oncogenes in human cancers. Targeting the KRAS protein, the most commonly altered family member in solid tumors, has been the toughest and most challenging in oncology research.

A specific mutation known as KRAS G12C is a major driver of tumor growth occurring broadly in solid tumors. In the U.S. about 13% of patients with non-small cell lung cancer (NSCLC) harbor the KRAS G12C mutation. It . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.